These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 24238495)

  • 1. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model.
    Murakami T; Takigawa N; Ninomiya T; Ochi N; Yasugi M; Honda Y; Kubo T; Ichihara E; Hotta K; Tanimoto M; Kiura K
    Lung Cancer; 2014 Jan; 83(1):30-6. PubMed ID: 24238495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
    Yasugi M; Takigawa N; Ochi N; Ohashi K; Harada D; Ninomiya T; Murakami T; Honda Y; Ichihara E; Tanimoto M; Kiura K
    Exp Cell Res; 2014 Aug; 326(2):201-9. PubMed ID: 24768699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of STAT3 with orally active JAK inhibitor, AZD1480, decreases tumor growth in Neuroblastoma and Pediatric Sarcomas In vitro and In vivo.
    Yan S; Li Z; Thiele CJ
    Oncotarget; 2013 Mar; 4(3):433-45. PubMed ID: 23531921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic inhibition of Jak2-Stat5 signaling By Jak2 inhibitor AZD1480 potently suppresses growth of both primary and castrate-resistant prostate cancer.
    Gu L; Liao Z; Hoang DT; Dagvadorj A; Gupta S; Blackmon S; Ellsworth E; Talati P; Leiby B; Zinda M; Lallas CD; Trabulsi EJ; McCue P; Gomella L; Huszar D; Nevalainen MT
    Clin Cancer Res; 2013 Oct; 19(20):5658-74. PubMed ID: 23942095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
    Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
    Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung Cancer.
    Ochi N; Isozaki H; Takeyama M; Singer JW; Yamane H; Honda Y; Kiura K; Takigawa N
    Exp Cell Res; 2016 Jun; 344(2):194-200. PubMed ID: 27180268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice.
    Stuart E; Buchert M; Putoczki T; Thiem S; Farid R; Elzer J; Huszar D; Waring PM; Phesse TJ; Ernst M
    Mol Cancer Ther; 2014 Feb; 13(2):468-74. PubMed ID: 24398427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo.
    Lee JH; Park KS; Alberobello AT; Kallakury B; Weng MT; Wang Y; Giaccone G
    Clin Cancer Res; 2013 Dec; 19(24):6777-86. PubMed ID: 24158701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of the efficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor (cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI, and histology.
    Loveless ME; Lawson D; Collins M; Nadella MV; Reimer C; Huszar D; Halliday J; Waterton JC; Gore JC; Yankeelov TE
    Neoplasia; 2012 Jan; 14(1):54-64. PubMed ID: 22355274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor.
    Alvarez JV; Greulich H; Sellers WR; Meyerson M; Frank DA
    Cancer Res; 2006 Mar; 66(6):3162-8. PubMed ID: 16540667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
    Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
    Haura EB; Zheng Z; Song L; Cantor A; Bepler G
    Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2-related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor-activating mutation.
    Harada D; Takigawa N; Ochi N; Ninomiya T; Yasugi M; Kubo T; Takeda H; Ichihara E; Ohashi K; Takata S; Tanimoto M; Kiura K
    Cancer Sci; 2012 Oct; 103(10):1795-802. PubMed ID: 22712764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer.
    Onn A; Isobe T; Wu W; Itasaka S; Shintani T; Shibuya K; Kenji Y; O'reilly MS; Fidler IJ; Herbst RS
    Clin Cancer Res; 2004 Dec; 10(24):8613-9. PubMed ID: 15623645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480.
    Xin H; Herrmann A; Reckamp K; Zhang W; Pal S; Hedvat M; Zhang C; Liang W; Scuto A; Weng S; Morosini D; Cao ZA; Zinda M; Figlin R; Huszar D; Jove R; Yu H
    Cancer Res; 2011 Nov; 71(21):6601-10. PubMed ID: 21920898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X; Zhou JY; Zhao J; Chen JJ; Ma SN; Zhou JY
    Anticancer Drugs; 2013 Nov; 24(10):1039-46. PubMed ID: 23962905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
    Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
    Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic potential of AZD1480 for the treatment of human glioblastoma.
    McFarland BC; Ma JY; Langford CP; Gillespie GY; Yu H; Zheng Y; Nozell SE; Huszar D; Benveniste EN
    Mol Cancer Ther; 2011 Dec; 10(12):2384-93. PubMed ID: 22027691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.